Lab-quality diagnostics. Right at your fingertip

With Our Proprietary Single-Molecule Immunoassay for the Point of Care

Towards Decentralized Diagnostics

The paradigm shift from centralized lab testing to home and Point-of-Care (POC) testing was long anticipated. Yet many POC solutions face the fundermantal constrains: high test cost, limited reliability, and insufficient analytical sensitivity. As a result, accurate diagnostics are still largely confined to centralized labs, creating delays, accessibility barriers, and significant healthcare system burden.

NanoSense is addressing these challenges by developing a single-molecule immunodiagnostic platform that delivers lab-grade sensitivity at the point of care. By overcoming the traditional trade-offs between cost , accuracy , and accessibility , NanoSense enables patients to assess critical health conditions directly—whether at home or in neighborhood clinics—without prolonged waiting times, complex workflows, or prohibitive costs.

Single Molecule Mechanical Selection (SMMS)

Sensitivity

An unambiguous signal can be generated by the capturing of a single target biomolecule, making our assay the genuine single molecule detection. Ultra sensitivity is the foundation for us to develop early screening for many diseases using blood samples.

Specificity

A first-of-its-kind mechanical force is employed to selectively eliminate nonspecific, weaker bindings, while specific, stronger bindings are retained. This invention safeguards the detection specificity in complicated biosamples.

Simplicity

Mix, load, flip and detect. For as simple as 4 steps and as fast as 30 minutes, ultra-sensitive, quantitative results are out.

SMMS vs Other Immunodiagnostic Technologies for Blood Biomarker Detection

Key Lab Verification Results

Initial testing revealed an 87.5% detection rate when using the SMMS assay on plasma samples spiked with 25 fM of pTau181. This result indicates that our assay's current Limit of Detection (LoD) is approximately 25 fM. We are actively working to improve the sensitivity further.

Publications

Clinical Validation Results

To be revealed in the near future

Collaborators

Our engineer with the first prototype, back in 2020

Mission & Vision

Our vision is to make high-quality immunodiagnostics accessible to everyone, anytime, anywhere, enabling earlier insights and proactive care rather than late-stage reaction.

Our Story

NanoSense was originated in the global crisis. As a team of scientists, we developed the SMMS technology to join the frontline battle against COVID-19. This experience solidified our core conviction: science is most powerful when it is pulled out of the lab and put to work for humanity. Today, we are channeling that same spirit of innovation and social responsibility into tackling a broader spectrum of global health challenges, transforming our laboratory breakthrough into a scalable POCT platform for disease detection and a healthier future.

Founders & Advisors

Prof. Yan Jie Founder & Scientific Advisor Professor of NUS Physics PI of Mechanobiology Institute, NUS

Prof. Rong Li Founder & Scientific Advisor Director of Mechanobiology Institute, NUS Bloomberg Distinguished Professor of Johns Hopkins School of Medicine

Ms. Summer Qu Xiaopeng Business Advisor Founder of Wedo Venture Partners

Let us hear from you

We welcome collaboration inquiries from research institutions, hospitals, and strategic partners globally.